Finepoint Capital LP 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Finepoint Capital LP disclosed 24 US equity positions worth $822.3m in its Q3 2024 13F filing. The largest position was QXO at 49.4% of the reported book, followed by 8L8C and RVMD.
What did Finepoint Capital LP own in Q3 2024? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | QXO QXO INC | Industrials | 49.4% | $406.1m | 25,750,781 | – | |
| 2 | 8L8C Liberty Broadband Corp | 18.7% | $154.2m | 1,994,510 | – | ||
| 3 | RVMD REVOLUTION MEDICINES INC | Healthcare | 4.0% | $33.2m | 731,960 | – | |
| 4 | ARGX Argenx SE | Healthcare | 3.6% | $29.5m | 54,428 | – | |
| 5 | ASND ASCENDIS PHARMA A/S | Healthcare | 3.5% | $28.4m | 190,072 | – | |
| 6 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 3.0% | $24.9m | 1,782,267 | – | |
| 7 | SWTXUSD SPRINGWORKS THERAPEUTICS INC | 2.5% | $20.9m | 650,852 | – | ||
| 8 | MLTX MoonLake Immunotherapeutics | Healthcare | 2.4% | $19.6m | 388,835 | – | |
| 9 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 2.0% | $16.7m | 133,535 | – | |
| 10 | LKFT GALAPAGOS NV | Healthcare | 2.0% | $16.1m | 557,762 | – | |
| 11 | ARVN ARVINAS INC | Healthcare | 1.7% | $14.1m | 574,378 | – | |
| 12 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 1.7% | $13.9m | 905,384 | – | |
| 13 | CYTK CYTOKINETICS INC | Healthcare | 1.6% | $13.5m | 256,449 | – | |
| 14 | RLAY RELAY THERAPEUTICS INC | Healthcare | 1.4% | $11.5m | 1,626,146 | – | |
| 15 | PROTHENA CORP PLC | 0.9% | $7.3m | 433,471 | – | ||
| 16 | SLDB SOLID BIOSCIENCES INC | Healthcare | 0.8% | $6.7m | 961,251 | – | |
| 17 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 0.7% | $5.7m | 707,404 | – | |
| 18 | Swiftmerge Acquisition Corp | 0.0% | $39.2k | 490,000 | – | ||
| 19 | Compass Digital Acquisition Corp | 0.0% | $28.1k | 459,906 | – | ||
| 20 | MONEYHERO LIMITED | 0.0% | $26.9k | 895,000 | – | ||
| 21 | Marblegate Acquisition Corp | 0.0% | $25.3k | 735,000 | – | ||
| 22 | LAKESHORE BIOPHARMA CO LTD | 0.0% | $24.2k | 489,999 | – | ||
| 23 | CALIDI BIOTHERAPEUTICS INC | 0.0% | $14.2k | 12,500 | – | ||
| 24 | CALIDI BIOTHERAPEUTICS INC | 0.0% | $8.6k | 655,200 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.